Status:
UNKNOWN
Thrombogenicity of Lipoprotein A: Laboratory Study Defining the Prothrombotic Effects of Lipoprotein A
Lead Sponsor:
South Tees Hospitals NHS Foundation Trust
Collaborating Sponsors:
Newcastle-upon-Tyne Hospitals NHS Trust
Conditions:
Cardiovascular Disease and Lipid Disorders
Cardiac Disease
Eligibility:
All Genders
18+ years
Brief Summary
Brief summary: Lipoprotein a (Lp(a)) is an independent risk factor for cardiovascular and cerebrovascular disease. Traditionally, the pathogenic role of Lp(a) has been linked to the atherogenic proces...
Detailed Description
Thrombogenicity of Lp(a) study is a two-centre, open-label, non-randomised, observational laboratory study defining the prothrombotic effects of Lp(a). The study is aimed to answer the question of eff...
Eligibility Criteria
Inclusion
- Adult patients with stable coronary artery disease and previous history of myocardial infarction currently receiving aspirin monotherapy;
- Age ≥ 18;
- Patients who can provide written informed consent for participation in the trial;
Exclusion
- Haematological disorders (anaemia, malignancy, bleeding disorder)
- Malignancy (currently diagnosed or under investigation)
- Current smokers
- Chronic liver disease
- End stage renal disease (eGFR\<30ml/min)
- Use of corticosteroids or non-steroidal anti-inflammatory agents
- Patients taking aspirin at dose of above 75mg daily
- Patients receiving anticoagulant treatment or antiplatelet treatment other than aspirin
- Unable to consent
Key Trial Info
Start Date :
May 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05330819
Start Date
May 1 2022
End Date
September 1 2022
Last Update
April 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
South Tees Hospitals NHS FT
Middlesbrough, Teesside, United Kingdom, TS4 3BW